Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B G Feagan

Showing results (11-20 of 75) with videos related to

Pageof 8
Sort By:
Alimentary Pharmacology & Therapeutics|May 6, 2017
Editorial: the impact of the placebo effect in Crohn's disease - author's replyV Jairath, B G Feagan
Alimentary Pharmacology & Therapeutics|August 5, 2003
Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithmW J Sandborn, B G Feagan
Alimentary Pharmacology & Therapeutics|June 7, 2014
Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease--authors' replyB G Levesque, B G Feagan
Lancet (London, England)|May 3, 1997
Cyclosporin in Crohn's diseaseB G Feagan, J W McDonald
Gastroenterology|March 29, 2001
Mesalamine maintenance therapy for Crohn's diseaseB G Feagan, J W McDonald
Lancet (London, England)|April 15, 1995
Ethics of n-of-1 trialsJ L Mahon, B G Feagan, A Laupacis
Alimentary Pharmacology & Therapeutics|February 19, 1998
Review article: Drug development in inflammatory bowel disease: budesonide--a model of targeted therapyR Hamedani, R D Feldman, B G Feagan
Alimentary Pharmacology & Therapeutics|September 20, 2007
Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remissionW J Sandborn, B G Feagan, G R Lichtenstein
Gastroenterology|January 1, 1996
Therapeutics and inflammatory bowel disease: a guide to the interpretation of randomized controlled trialsB G Feagan, J W McDonald, J J Koval
Journal of Clinical Epidemiology|October 1, 1996
Does self-administration of a quality of life index for inflammatory bowel disease change the results?E J Irvine, B G Feagan, C J Wong
Pageof 8

Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
Alimentary Pharmacology & Therapeutics|May 6, 2017
Editorial: the impact of the placebo effect in Crohn's disease - author's replyV Jairath, B G Feagan
Alimentary Pharmacology & Therapeutics|August 5, 2003
Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithmW J Sandborn, B G Feagan
Alimentary Pharmacology & Therapeutics|June 7, 2014
Letter: Limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease--authors' replyB G Levesque, B G Feagan
Lancet (London, England)|May 3, 1997
Cyclosporin in Crohn's diseaseB G Feagan, J W McDonald
Gastroenterology|March 29, 2001
Mesalamine maintenance therapy for Crohn's diseaseB G Feagan, J W McDonald
Lancet (London, England)|April 15, 1995
Ethics of n-of-1 trialsJ L Mahon, B G Feagan, A Laupacis
Alimentary Pharmacology & Therapeutics|February 19, 1998
Review article: Drug development in inflammatory bowel disease: budesonide--a model of targeted therapyR Hamedani, R D Feldman, B G Feagan
Alimentary Pharmacology & Therapeutics|September 20, 2007
Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remissionW J Sandborn, B G Feagan, G R Lichtenstein
Gastroenterology|January 1, 1996
Therapeutics and inflammatory bowel disease: a guide to the interpretation of randomized controlled trialsB G Feagan, J W McDonald, J J Koval
Journal of Clinical Epidemiology|October 1, 1996
Does self-administration of a quality of life index for inflammatory bowel disease change the results?E J Irvine, B G Feagan, C J Wong
Pageof 8